Scorpius Holdings Inc SCPX

Healthcare Biotechnology

Scorpius Holdings, Inc., formerly NightHawk Biosciences, Inc., is an integrated contract development and manufacturing company. The Company is focused on advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. Its analytical services include development of a comprehensive range of analytical test methods to characterize complex biologics, including cell therapy-based products, protein therapeutics, vaccines and advanced therapies. Its Clinical Biomanufacturing includes cGMP Mammalian Cell Culture, and cGMP Microbial Fermentation. Its San Antonio facility is focused on the commercial-scale manufacturing of biodefense-focused molecules and biologics therapeutics. Its biomanufacturing services focus on accelerating product development timelines from pre-clinical evaluation to first-in-human studies.

NYSEAM:SCPX - Post by User

Scorpius Holdings Inc > Good update taken from Yahoo chat line

<< Previous

Bullboard Posts

Next >>

Post by TanzaniteMotherLodeon Mar 10, 2020 6:50am

224 Views

Post# 30787060

Good update taken from Yahoo chat line

Why I think Monday will be a good day:

1. There’s a short sale restriction (SSR) Monday

2. It’s a popular stock so there will be good volume with much less shorts occurring

3. The last time there was an SSR activated (3/4), the stock recovered FULLY from a really terrible day the day before

4. The CEO is business/stock savvy. He put out a PR on 3/4 in conjunction with the SR, which helped the stock price to recover. I wouldn’t be surprised if he puts out a PR on Monday as well

5. News outlets might catch onto the fact that what HTBX is working on for coronavirus actually prevents AND treats. It’s basically a vaccine (prevention) and drug (treatment) in one. This is HIGHLY UNIQUE!

6. I think the other vaccine stocks are trading at their current peaks (INO, MRNA, NVAX) and are better candidates for shorting. I think the shorts will play over there.

7. There’s potential for a really nice short squeeze with all of the factors at play

Why I think it will be good short term for the stock— there’s a lot of good news to report:
1. Company could announce officially getting gov’t funding for the coronavirus vaccine

2. The first patient enrolled in HS-110 ComPACT Phase 1 will be given the last dose on Monday (3/9). Phase 1 focused on safety so I wouldn’t be surprised to see an update

3. PTX-35 is awaiting FDA approval and the start of Phase 1. The company stated it expected the FDA to approve in Q2

4. Their biggest drug is HS-110 ImPACT which is in Phase 2 in partnership with Bristol Myers Squibb. Results so far have been extremely positive, and it’s possible Bristol Myers could be a buyout candidate before Phase 2 completes since the results have been so good.

This is based off my own research, and I thought I’d share. I highly recommend you do your own research and not make any crazy decisions based off of comments you see in forums (including mine).

I plan to re-post this on Sunday and on Monday morning. Feel free to share!

<< Previous

Bullboard Posts

Next >>

Nord Precious Metals reveals silver zone at Castle East